Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free BIOG Stock Alerts

The Biotech Growth Trust (BIOG) Competitors

The Biotech Growth Trust logo
GBX 1,724 +26.00 (+1.53%)
As of 12:03 PM Eastern
Compare

BIOG vs. IHP, TMPL, JFJ, FCSS, and GROW

Should you buy The Biotech Growth Trust stock or one of its competitors? The Biotech Growth Trust's main competitors and comparable companies include IntegraFin (IHP), Temple Bar (TMPL), JPMorgan Japanese (JFJ), Fidelity China Special (FCSS), and Molten Ventures (GROW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does The Biotech Growth Trust compare to IntegraFin?

IntegraFin (LON:IHP) and The Biotech Growth Trust (LON:BIOG) are both small-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

The Biotech Growth Trust has a net margin of 96.47% compared to IntegraFin's net margin of 28.60%. The Biotech Growth Trust's return on equity of 48.26% beat IntegraFin's return on equity.

Company Net Margins Return on Equity Return on Assets
IntegraFin28.60% 27.60% 20.29%
The Biotech Growth Trust 96.47%48.26%12.39%

IntegraFin has a beta of 1.269, meaning that its stock price is 27% more volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.588, meaning that its stock price is 41% less volatile than the broader market.

The Biotech Growth Trust has lower revenue, but higher earnings than IntegraFin. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than IntegraFin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntegraFin£165.40M7.83£52.54M£19.1020.52
The Biotech Growth Trust£133.86M2.46£83.83M£558.003.09

IntegraFin presently has a consensus price target of GBX 435, indicating a potential upside of 10.97%. Given IntegraFin's stronger consensus rating and higher probable upside, analysts plainly believe IntegraFin is more favorable than The Biotech Growth Trust.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IntegraFin
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
The Biotech Growth Trust
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

44.2% of IntegraFin shares are owned by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are owned by institutional investors. 14.5% of IntegraFin shares are owned by insiders. Comparatively, 3.0% of The Biotech Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, IntegraFin had 2 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 3 mentions for IntegraFin and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.61 beat IntegraFin's score of 0.87 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IntegraFin
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
The Biotech Growth Trust
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

IntegraFin beats The Biotech Growth Trust on 11 of the 16 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Temple Bar?

The Biotech Growth Trust (LON:BIOG) and Temple Bar (LON:TMPL) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, The Biotech Growth Trust and The Biotech Growth Trust both had 1 articles in the media. The Biotech Growth Trust's average media sentiment score of 1.61 beat Temple Bar's score of 0.75 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
The Biotech Growth Trust
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Temple Bar
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

10.5% of The Biotech Growth Trust shares are held by institutional investors. Comparatively, 10.7% of Temple Bar shares are held by institutional investors. 3.0% of The Biotech Growth Trust shares are held by company insiders. Comparatively, 0.2% of Temple Bar shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

The Biotech Growth Trust has a net margin of 96.47% compared to Temple Bar's net margin of 82.15%. The Biotech Growth Trust's return on equity of 48.26% beat Temple Bar's return on equity.

Company Net Margins Return on Equity Return on Assets
The Biotech Growth Trust96.47% 48.26% 12.39%
Temple Bar 82.15%27.93%7.08%

The Biotech Growth Trust has a beta of 0.588, indicating that its share price is 41% less volatile than the broader market. Comparatively, Temple Bar has a beta of 1.155, indicating that its share price is 16% more volatile than the broader market.

Temple Bar has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Temple Bar, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Biotech Growth Trust£133.86M2.46£83.83M£558.003.09
Temple Bar£281.60M4.59£154.90M£97.004.36

Summary

The Biotech Growth Trust and Temple Bar tied by winning 6 of the 12 factors compared between the two stocks.

How does The Biotech Growth Trust compare to JPMorgan Japanese?

JPMorgan Japanese (LON:JFJ) and The Biotech Growth Trust (LON:BIOG) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

JPMorgan Japanese has a net margin of 96.52% compared to The Biotech Growth Trust's net margin of 96.47%. The Biotech Growth Trust's return on equity of 48.26% beat JPMorgan Japanese's return on equity.

Company Net Margins Return on Equity Return on Assets
JPMorgan Japanese96.52% 20.00% 8.06%
The Biotech Growth Trust 96.47%48.26%12.39%

JPMorgan Japanese has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than JPMorgan Japanese, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JPMorgan Japanese£245.55M5.30£194.81M£149.065.78
The Biotech Growth Trust£133.86M2.46£83.83M£558.003.09

JPMorgan Japanese has a beta of 1.041, meaning that its stock price is 4% more volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.588, meaning that its stock price is 41% less volatile than the broader market.

18.9% of JPMorgan Japanese shares are owned by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are owned by institutional investors. 0.1% of JPMorgan Japanese shares are owned by company insiders. Comparatively, 3.0% of The Biotech Growth Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than JPMorgan Japanese. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for JPMorgan Japanese. The Biotech Growth Trust's average media sentiment score of 1.61 beat JPMorgan Japanese's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
JPMorgan Japanese Neutral
The Biotech Growth Trust Very Positive

Summary

JPMorgan Japanese beats The Biotech Growth Trust on 7 of the 13 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Fidelity China Special?

The Biotech Growth Trust (LON:BIOG) and Fidelity China Special (LON:FCSS) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

10.5% of The Biotech Growth Trust shares are owned by institutional investors. Comparatively, 7.8% of Fidelity China Special shares are owned by institutional investors. 3.0% of The Biotech Growth Trust shares are owned by company insiders. Comparatively, 0.1% of Fidelity China Special shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

The Biotech Growth Trust has a net margin of 96.47% compared to Fidelity China Special's net margin of 81.41%. The Biotech Growth Trust's return on equity of 48.26% beat Fidelity China Special's return on equity.

Company Net Margins Return on Equity Return on Assets
The Biotech Growth Trust96.47% 48.26% 12.39%
Fidelity China Special 81.41%9.12%N/A

The Biotech Growth Trust has a beta of 0.588, indicating that its share price is 41% less volatile than the broader market. Comparatively, Fidelity China Special has a beta of 0.908, indicating that its share price is 9% less volatile than the broader market.

Fidelity China Special has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Fidelity China Special, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Biotech Growth Trust£133.86M2.46£83.83M£558.003.09
Fidelity China Special£146.54M8.23£997.06M£29.758.91

In the previous week, The Biotech Growth Trust and The Biotech Growth Trust both had 1 articles in the media. The Biotech Growth Trust's average media sentiment score of 1.61 beat Fidelity China Special's score of 1.29 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
The Biotech Growth Trust
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Fidelity China Special
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

The Biotech Growth Trust beats Fidelity China Special on 7 of the 12 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Molten Ventures?

Molten Ventures (LON:GROW) and The Biotech Growth Trust (LON:BIOG) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

The Biotech Growth Trust has lower revenue, but higher earnings than Molten Ventures. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Molten Ventures, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molten Ventures£148M7.96-£33.58M£69.009.86
The Biotech Growth Trust£133.86M2.46£83.83M£558.003.09

40.6% of Molten Ventures shares are held by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are held by institutional investors. 1.6% of Molten Ventures shares are held by insiders. Comparatively, 3.0% of The Biotech Growth Trust shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Molten Ventures has a beta of 1.9564402, indicating that its share price is 96% more volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.588, indicating that its share price is 41% less volatile than the broader market.

Molten Ventures currently has a consensus price target of GBX 638.67, indicating a potential downside of 6.08%. Given Molten Ventures' stronger consensus rating and higher probable upside, equities analysts plainly believe Molten Ventures is more favorable than The Biotech Growth Trust.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Molten Ventures
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
The Biotech Growth Trust
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

The Biotech Growth Trust has a net margin of 96.47% compared to Molten Ventures' net margin of 75.09%. The Biotech Growth Trust's return on equity of 48.26% beat Molten Ventures' return on equity.

Company Net Margins Return on Equity Return on Assets
Molten Ventures75.09% 9.21% -3.46%
The Biotech Growth Trust 96.47%48.26%12.39%

In the previous week, Molten Ventures had 1 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 2 mentions for Molten Ventures and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.61 beat Molten Ventures' score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Molten Ventures
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
The Biotech Growth Trust
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Molten Ventures beats The Biotech Growth Trust on 9 of the 16 factors compared between the two stocks.

Get The Biotech Growth Trust News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIOG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIOG vs. The Competition

Export
MetricThe Biotech Growth TrustCapital Markets IndustryFinance SectorLON Exchange
Market Cap£329.42M£5.67B£14.11B£2.88B
Dividend YieldN/A7.39%5.87%6.10%
P/E Ratio3.0938.4029.39368.46
Price / Sales2.461,235.89514.6183,426.45
Price / Cash87.7448.2830.4227.89
Price / Book1.603.742.847.08
Net Income£83.83M£417.12M£1.31B£5.89B
7 Day Performance1.65%0.38%0.63%0.54%
1 Month Performance8.16%1.34%1.58%3.02%
1 Year Performance103.30%6.49%11.85%64.50%

The Biotech Growth Trust Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIOG
The Biotech Growth Trust
N/AGBX 1,724
+1.5%		N/A+100.2%£329.42M£133.86M3.09N/A
IHP
IntegraFin
3.6017 of 5 stars		GBX 395
flat		GBX 435
+10.1%		+13.5%£1.30B£165.40M20.683,520
TMPL
Temple Bar
N/AGBX 425
flat		N/A+23.9%£1.30B£281.60M4.38N/A
JFJ
JPMorgan Japanese
N/AGBX 857.93
0.0%		N/A+24.5%£1.30B£245.55M5.76N/A
FCSS
Fidelity China Special
N/AGBX 264.69
+0.6%		N/A-9.5%£1.21B£146.54M8.90N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BIOG) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel